Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Zacks Investment Research on MSN2d
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
It was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Sarepta Therapeutics ...
Zacks Investment Research on MSN3d
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after ...
This Is What Whales Are Betting On Sarepta Therapeutics
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...
StockStory.org on MSN4d
Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...
Sarepta Therapeutics (SRPT) Receives a Buy from Evercore ISI
In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 4% After Analyst Downgrade
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...
Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...
Deutsche Bank Aktiengesellschaft Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target reduced by stock analysts at Deutsche Bank ...
Sarepta: Should Investors Run For The Exit?
Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Nasdaq3d
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular ...